Related Experiment Video

Updated: Dec 9, 2025

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.0K

Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in

Kumar Nikhil1, Mohini Kamra1, Asif Raza1

  • 1Department of Chemistry and Purdue University Center for Cancer Research 560 Oval Drive, West Lafayette, IN, 47907, USA.

Cancer Letters
|September 15, 2020
PubMed

Insights

Researchers discovered LIMK2 downregulates PTEN, driving aggressive prostate cancer. Inhibiting LIMK2 may halt castration-resistant prostate cancer (CRPC) progression and drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Androgen deprivation therapy (ADT) and androgen receptor (AR) inhibitors are primary treatments for aggressive prostate cancer.
  • Resistance to ADT often involves PI3K pathway activation, frequently linked to PTEN loss, leading to castration-resistant prostate cancer (CRPC).

Purpose of the Study:

  • To uncover a novel mechanism driving CRPC pathogenesis.
  • To identify therapeutic targets for halting prostate cancer progression and drug resistance.

Main Methods:

  • Investigated the role of LIMK2 in PTEN regulation in CRPC models.
  • Utilized in vivo and in vitro experiments, including PTEN knockout and wild-type mouse models.
  • Examined the feedback loop between PTEN and LIMK2 and the link to hypoxia.

Main Results:

  • LIMK2 was identified as a key driver of CRPC by downregulating PTEN.
  • LIMK2 phosphorylates and degrades PTEN, promoting aggressive cancer phenotypes.
  • A feedback loop between PTEN and LIMK2 was established, with PTEN degrading LIMK2.
  • LIMK2 mediates PTEN degradation in response to hypoxia in CRPC.

Conclusions:

  • The LIMK2-PTEN regulatory loop is a critical mechanism in CRPC development.
  • Inhibiting LIMK2 offers a therapeutic strategy to restore PTEN stability and function.
  • Targeting LIMK2 could halt CRPC progression, ADT resistance, and drug resistance.
Keywords:
AKTCastration resistant prostate cancerEMTLIMK2PI3KPTEN

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K